Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents

摘要: Age-related macular degeneration (AMD) is the leading cause of severe vision loss in adults over age 65 years. The advent anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections has revolutionized management exudative AMD. However, multiple case series sustained elevated intraocular pressure (IOP) after anti-VEGF agents have been reported. Sustained IOP reported with all being used ophthalmology and even patients without any prior history glaucoma. No clear correlations to injection frequency or patient characteristics emerged from reports so far, but it appears that pre-existing glaucoma ocular hypertension those receiving a greater number shorter intervals may be at higher risk for developing related agents. Until future studies elucidate pathophysiology following injections, prudent recognize possibility elevations association therapy. Treating physicians should look subtle optic nerve head changes measurements suspicious low threshold treating if likely require injections. Ocular amenable anti-glaucoma treatment every effort made preserve peripheral these where central already threatened by